Navigation Links
PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
Date:10/18/2007

le improvement in the staining for dystrophin from muscle biopsies. Response did not appear to be dependent on type of nonsense mutation.

Blood levels of muscle-derived creatine kinase were also measured as assessments of muscle integrity. Statistically significant reductions in the concentrations of muscle-derived creatine kinase were observed during PTC124 treatment. In addition, several parents and teachers reported that boys participating in the study had improvements in terms of greater activity level and increased endurance during the study duration.

"We are very encouraged by these results, which show improvements in critical biomarkers of DMD," said presenter and study investigator, Carsten Bonnemann, M.D., Assistant Professor Neurology and Pediatrics, Children's Hospital of Philadelphia and University of Pennsylvania School of Medicine and Co-Director of the Neuromuscular Program, Children's Hospital of Philadelphia. "The combined in vitro and in vivo evidence of enhanced dystrophin expression and reduced muscle fragility offer signals of pharmacological activity that we hope to translate into potential clinical benefit for patients with DMD."

"Coupled with the emerging safety profile of PTC124, these data provide the impetus for moving forward rapidly to initiate longer-term studies for boys with DMD," said Langdon Miller, M.D., Chief Medical Officer of PTC. "We are actively working with our clinical investigators and the regulatory agencies to finalize plans for additional clinical trials and we look forward to commencing these studies in the coming months."

Stuart W. Peltz, Ph.D., President and Chief Executive Officer of PTC Therapeutics added, "These results, combined with the data presented earlier this month at the Child Neurology Society meeting and North American Cystic Fibrosis Conference, further support our belief that PTC124 represents a paradigm shift in the treatment of genetic disorders. Our future plans for PTC124 inc
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... PARK, N.J. , July 30, 2015  Unichem ... voluntarily recalling one lot of Hydrochlorothiazide tablets 25 mg ... been initiated as a precautionary measure due to the ... of the product. The risk associated ... Hydrochlorothiazide tablet is the increased probability of experiencing Clopidogrel,s ...
(Date:7/30/2015)... July 30, 2015 PTC Therapeutics, Inc. (NASDAQ: ... reported financial results for the second quarter ending June ... many fronts across the organization.  We are excited to ... dystrophy clinical trial ever conducted with topline results expected ... Chief Executive Officer, PTC Therapeutics, Inc. "Translarna is now ...
(Date:7/30/2015)... , July 30, 2015  Cleveland Clinic President ... 2015 keynote address last month that industry is compelled ... order to gain the efficiencies—and develop the transformational innovations ... Dr. Barsoum,s comments were preceded by Doug Kohrs ... and OMTEC moderator, who stressed that industry must add ...
Breaking Medicine Technology:Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2
... MUNDELEIN, Ill. , July 1 ... and information systems developer, today announces executive changes in ...  John Kershaw, President & CEO, Sysmex America Inc. has ... Secretary; Judy Bosko as Vice President of ...
... SCHAUMBURG, Ill. , July 1 ... today announced that the U.S. Food and Drug Administration ... sodium injection, USP. Heparin is a vital anticoagulant, preventing ... within the blood, routinely used in surgical and dialysis ...
Cached Medicine Technology:Sysmex America Announces Executive Leadership Changes 2FDA Approves Sagent Pharmaceuticals' Heparin Sodium Injection, USP 2FDA Approves Sagent Pharmaceuticals' Heparin Sodium Injection, USP 3FDA Approves Sagent Pharmaceuticals' Heparin Sodium Injection, USP 4
(Date:8/1/2015)... , ... August 02, 2015 , ... Back packs can ... a school, however, back packs can wreck havoc on a kid's spine. With school ... supplies to and from school. Make sure you are aware of how to help ...
(Date:8/1/2015)... ... ... Tina Wilcoxson, owner of Freeport Maine’s Royal River Natural Foods, was named one ... Federation, the largest retail trade association in the world, for her “advocacy and engagement” ... named as such. According to the NRF’s website, Retail Champions are “Main Street business ...
(Date:8/1/2015)... ... August 01, 2015 , ... BeverlyD, owner and founder of ... making hers the very first small business donation to kick off the campaign for ... thirty years. Her legacy includes a complete line of raw, organic hair care products, ...
(Date:7/31/2015)... New York (PRWEB) , ... July 31, 2015 , ... ... strut their stuff, Super-Sod debuted their new type of sod called Leisure Time(TM) ... trademark application in process. , To commemorate introduction of this new type of sod, ...
(Date:7/31/2015)... ... July 31, 2015 , ... Recently touted ... in predictive health analytics , Jvion continues to disrupt the predictive analytic ... software that targets patient and population level illness to drive prevention and better ...
Breaking Medicine News(10 mins):Health News:Local AlignLife Doctor Donates Time to Check Back Packs 2Health News:Local Retail Advocate Wins National Recognition 2Health News:March4thforWellBeing Foundation Kickoff 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2
... Australia has earmarked $74 million to combat the bird flu ... Howard was to announce the funding in Busan, Korea, where ... forum., ,International agencies, like the World Health Organization (WHO), ... percent would go on a simulation exercise run by APEC ...
... had problems with the placenta during pregnancy are at an ... reports BBC online., ,Placenta is a tube through which ... mother and gets rid of waste products. , ,Doctor ... studied over a million women who were free from cardiovascular ...
... the World Health Organization (WHO) experts, concerted efforts, ... eradication of the five neglected tropical diseases from ... years. , WHO has identified five tropical ... (kala azar), soil transmitted helminths (STH) and yaws ...
... scientists present the first proof that simple exposure to cold weather ... your mother always warned you to wrap up warm to // ... point. , Scientists say they have the first proof that ... , Their study findings will appear in this week’s The ...
... the national nursing shortage by producing more qualified nursing ... Robert W. Woodruff Foundation has awarded // $995,000 to ... support its new doctorate of nursing practice program, the ... ,Thanking the Atlanta-based Woodruff Foundation, a private organization, for ...
... graduate, Leena Bahl Palomo, D.D.S and M.S.D, tracked 60 ... for osteoporosis and who had also visited the Case ... Case's department of Periodontology; and James Liu, chair of ... of Cleveland collaborated with Ms Palomo in the study. ...
Cached Medicine News:Health News:Placenta Problems In Pregnancy Linked To Early Heart Disease 2Health News:Concerted Effort Imperative For Elimination Of Tropical Diseases: WHO 2Health News:Scientist Affirm Mom’s Advice - Keep Yourself Wrapped Up To Avoid Cold 2Health News:Woodruff Foundation Grant To Support Doctorate Of Nursing Practice Program 2Health News:Drugs Used In Osteoporosis Can Help Prevent Periodontal Bone Loss 2
... a centimeter ruler etched into the gel tray ... includes apparatus, connecting cables, three 7x10 cm gel ... three 14-well combs. The Chameleon can accomodate up ... of a maximum of 120 samples with a ...
... of a Separation-Control unit for system control ... gel staining. The optional PhastTransfer Kit quickly ... unit. Electrophoresis is performed on a thermostatic ... 0 to +70 C. Multi-step programming capability ...
... The SEA 2000 apparatus and ready-to-use gels ... for analysis of nucleic acids by submerged ... complete this system, offering full compatibility and ... Besides the SEA 2000 and a unique ...
... SEA 2000 apparatus and ready-to-use gels are ... analysis of nucleic acids by submerged gel ... this system, offering full compatibility and optimal ... the SEA 2000 and a unique staining ...
Medicine Products: